Crystalline pharmaceutically active ingredients

摘要

The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis.;

主权项

1. A crystalline Form V rosuvastatin zinc (2:1) salt [hemizinc salt of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid] of Formula (I) which has X-ray diffraction lines measured by CuKα radiation at the following diffraction angle 2Θ (±0.2° 2Θ): 4.746 degrees; or X-ray diffraction lines measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 4.746 and 15.371 degrees; or a powder X-ray diffractogram of FIG. 1; or the following X-ray diffraction lines measured by the CuKα radiation:2Θ [°]d-value [Å]Relative intensity [%]4.76418.5324100.05.87315.035220.98.9419.882311.19.5479.256112.510.9608.066420.711.7737.511119.012.2247.234720.612.8706.87338.813.1186.743821.113.9796.330313.914.4016.14549.815.3715.759961.615.9975.535913.216.3575.414810.416.8525.25708.017.6415.02356.917.9954.925629.618.7834.72065.819.3944.573331.919.9774.44119.220.7414.27925.120.9594.23524.621.7004.092212.322.2633.989917.522.7363.90809.723.3673.803814.923.6593.757512.924.2353.669529.824.7163.599210.525.2453.525019.326.0343.41999.526.4853.36278.027.0283.296412.928.0163.18248.328.6673.11158.029.6623.00938.630.9672.88549.232.6682.73906.933.0322.70968.033.3422.68517.233.9892.63555.634.4522.60116.8.